Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences
Kodiak Sciences (Nasdaq: KOD), a biopharmaceutical company focused on retinal diseases, announced upcoming presentations at several key conferences.
They'll present at the Jefferies Healthcare Conference on June 6, 2024, in New York, and the Goldman Sachs 45th Annual Global Healthcare Conference on June 13, 2024, in Miami Beach. Live webcasts will be available on their website.
Kodiak will also attend the Clinical Trials at the Summit 2024 on June 8 in Park City. Key presentations will be made by Quan Dong Nguyen, M.D., and CEO Victor Perlroth, M.D., highlighting their bispecific anti-IL-6 and anti-VEGF programs, KSI-501 and KSI-101.
Slides will be accessible on Kodiak's website during the presentations.
- Kodiak Sciences will present at prestigious investor conferences, signaling strong industry engagement and visibility.
- Presentations at the Jefferies Healthcare Conference and Goldman Sachs Global Healthcare Conference may attract potential investors.
- Participation in the Clinical Trials at the Summit 2024 will showcase Kodiak's clinical pipeline, potentially boosting investor confidence.
- Live webcasts and presentation slides available online enhance transparency and accessibility for stakeholders.
- No new clinical data or financial results were disclosed in the announcement, potentially leaving investors wanting more substantial updates.
- The PR lacks specific timelines or milestones for their clinical trials, which could be a concern for investors seeking concrete progress indicators.
- Jefferies Healthcare Conference, June 6, 2024, 8:00 AM ET (5:00 AM PT),
New York, New York - Goldman Sachs 45th Annual Global Healthcare Conference, June 13, 2024, 8:00 AM ET (5:00 AM PT),
Miami Beach, Florida
A live webcast of both presentations will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the events.
In addition, Kodiak will participate in the upcoming Clinical Trials at the Summit 2024 meeting, being held on June 8 from 8:00am – 5:30pm (MT) in
- Title: Bispecific Anti-IL-6 Anti-VEGF Programs: KSI-501 in Retinal Vascular Disease and KSI-101 in Macular Edema Secondary to Inflammation
Time: 7:49 – 7:53 AM MT
Presenter: Quan Dong Nguyen, M.D., Professor of Ophthalmology and Director of Uveitis and Ocular Inflammation, Byers Eye Institute, Stanford University School of Medicine. - Title: Update on KSI Programs for Retinal Diseases
Time: 1:10 – 1:14 PM MT
Presenter: Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences
Slides of these presentations will be made available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ at the beginning of the presentations.
About Kodiak Sciences Inc.
Kodiak Sciences (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing, and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of protein-based and chemistry-based therapies and has been at the core of Kodiak's discovery engine. We are developing a portfolio of three clinical programs, two of which are late-stage today and derived from our ABC Platform and one which is platform-independent and which we believe can progress rapidly into pivotal studies.
Kodiak's lead investigational medicine, tarcocimab, is a novel anti-VEGF antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases including diabetic retinopathy, the leading cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world.
KSI-501 is our second investigational medicine, a first-in-class anti-IL-6, VEGF-trap bispecific antibody biopolymer conjugate designed to inhibit both IL-6 mediated inflammation and VEGF-mediated angiogenesis and vascular permeability. KSI-501 is being developed for the treatment of high prevalence retinal vascular diseases to address the unmet needs of extended durability and targeting multiple disease biologies for differentiated efficacy. Phase 1b data for KSI-501 was presented in February 2024, and the Phase 3 DAYBREAK study of KSI-501 in wet AMD is scheduled to be actively screening patients in mid-2024.
Additionally, Kodiak is developing a third product candidate, KSI-101, a novel anti-IL-6, VEGF-trap bispecific protein, the unconjugated protein portion of KSI-501. Kodiak intends to develop KSI-101 for the treatment of retinal inflammatory diseases, as currently there are no available intravitreal biologic therapies addressing the spectrum of inflammatory conditions of the retina.
Kodiak has expanded its early research pipeline of duet and triplet inhibitors that embed small molecules and other active pharmaceutical ingredients ("API") in the biopolymer backbone to enable targeted, high drug-antibody ratio ("DAR") medicines. The diverse API's are designed to be released over time to achieve targeted, multi-specific and tailored modulation of biological pathways. The unique combination of high DAR and tailored therapeutic benefit offers potential for broad application to multifactorial ophthalmic and systemic diseases.
For more information, please visit www.kodiak.com.
Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.
View original content:https://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-upcoming-investor-and-clinical-conferences-302158588.html
SOURCE Kodiak Sciences Inc.
FAQ
When will Kodiak Sciences present at the Jefferies Healthcare Conference?
What is the date and time for Kodiak's presentation at the Goldman Sachs Global Healthcare Conference?
Where can I watch the live webcasts of Kodiak's upcoming presentations?
What will Kodiak Sciences present at the Clinical Trials at the Summit 2024?
Who will present Kodiak's programs at the Clinical Trials at the Summit 2024?
What topics will be covered in Kodiak's presentations at the Clinical Trials at the Summit 2024?
